USA-based neurodegenerative disorders specialist Annovis Bio (NYSE: ANVS) saw its shares plunge 60% to $7.28 by close of trading, despite what it said were positive results for its Alzheimer’s disease (AD) candidate.
The company announced the data from its Phase II/III Alzheimer study of buntanetap in mild to moderate Alzheimer’s disease patients. Based on these data, Annovis says it plans to conduct a pivotal Phase III trial in biomarker-positive early AD patients.
Buntanetap is an oral molecule that selectively binds to an iron-responsive element in the mRNA of amyloid precursor protein (APP) and other neurotoxic proteins and inhibits their translation. Through this mechanism, buntanetap was shown to decrease the production of amyloid beta (Aβ), tau, alpha-Synuclein (αSYN), and TDP43.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze